This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Argenx Bv, University of Bern. Active years: 2023.
Company Filing History:
1 out of 30 
1 out of 26 Years Active: 2023
Title: Carsten Riether: Innovator in Cancer Therapy
Introduction
Carsten Riether is a notable inventor based in Ghent, Belgium. He has made significant contributions to the field of cancer treatment, particularly through his innovative approaches to combination therapies.
Latest Patents
Riether holds a patent for a combination therapy targeting malignancies, specifically myeloid malignancies such as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). His patent describes methods that utilize an antibody or antigen-binding fragment that binds to CD70, in conjunction with a BCL-2 inhibitor. Notably, the antibody used in certain embodiments is ARGX-110 (cusatuzumab), while the BCL-2 inhibitor is venetoclax. This combination has shown potential for synergistic treatment of AML, and may also include additional anti-cancer agents. He has 1 patent related to this innovative therapy.
Career Highlights
Throughout his career, Carsten Riether has worked with prominent organizations, including Argenx and the University of Bern. His work has focused on advancing therapeutic strategies for cancer treatment, contributing to the development of effective therapies for patients.
Collaborations
Riether has collaborated with notable colleagues such as Samson Fung and Adrian Ochsenbein. These partnerships have played a crucial role in enhancing the research and development of his innovative therapies.
Conclusion
Carsten Riether's contributions to cancer therapy through his innovative patent demonstrate his commitment to improving treatment options for patients with myeloid malignancies. His work continues to inspire advancements in the field of oncology.